Evidence map›Paper›PMID 14975041›Full record

ReviewCritical care (London, England)2004

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Cheryl L Holmes, Donald W Landry, John T Granton

Open access · goldAbstract readReview
In one paragraph

Review in Critical care (London, England), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 189 citations in OpenAlex.

  1. Guideline
  2. Efficacy and Safety of Vasopressin and Terlipressin in Preterm Neonates: A Systematic Review.International journal of environmental research and public health · 2022
    Pooled it
  3. Trial
  4. Trial
  5. Serum vasopressin response in patients with intradialytic hypotension: a pilot study.Clinical journal of the American Society of Nephrology : CJASN · 2008
    Trial
  6. [Vasopressors in septic shock: the old and the new].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026
    Review
  7. Article
  8. Review
  9. Hemodynamic rescue after blast injury: intravenous administration outperforms intramuscular vasopressin in a swine model.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Vasopressin associated hyponatremia in critically ill children: A cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Cheryl L HolmesDepartment of Medicine, Division of Critical Care, Kelowna General Hospital, Kelowna BC, Canada.
Donald W Landry
John T Granton
Columbia University · USKelowna General Hospital · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-sensitive K+ channels, nitric oxide pathways, and interaction with adrenergic agents. We explore the complex and contradictory studies of vasopressin on cardiac inotropy and coronary vascular tone. Finally, we summarize the clinical studies of vasopressin in shock states, which to date have been relatively small and have focused on physiologic outcomes. Because of potential adverse effects of vasopressin, clinical use of vasopressin in vasodilatory shock should await a randomized controlled trial of the effect of vasopressin's effect on outcomes such as organ failure and mortality.

Indexed as

Cardiovascular Physiological PhenomenaAnimalsClinical Trials as TopicHumansMuscle ContractionMuscle, Smooth, VascularMyocardial ContractionPotassium ChannelsReceptors, VasopressinShock, SepticVasodilator AgentsVasopressinsPotassium ChannelsReceptors, VasopressinVasodilator AgentsVasopressins

Identifiers

PMID14975041
PMCPMC420051
OpenAlexW2134771022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.